Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-02-16
2011-12-13
Seaman, D M (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08076356
ABSTRACT:
A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof;and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
REFERENCES:
patent: 3050525 (1962-08-01), Bicking
patent: 3754887 (1973-08-01), Brantley
patent: 4183854 (1980-01-01), Crossley
patent: 6043246 (2000-03-01), Fukami et al.
patent: 6106864 (2000-08-01), Dolan et al.
patent: 6339099 (2002-01-01), Lam et al.
patent: 6387900 (2002-05-01), Pevarello et al.
patent: 6514977 (2003-02-01), Anantanarayan et al.
patent: 6525046 (2003-02-01), Cirillo et al.
patent: 6617324 (2003-09-01), Naraian et al.
patent: 2002/0025963 (2002-02-01), Lam et al.
patent: 2003/0069258 (2003-04-01), Lam et al.
patent: 2003/0134843 (2003-07-01), Lubisch et al.
patent: 2003/0195221 (2003-10-01), Cai et al.
patent: 2004/0063772 (2004-04-01), Quan et al.
patent: 2004/0176325 (2004-09-01), Munson et al.
patent: 2004/0180896 (2004-09-01), Munson et al.
patent: 2004/0192653 (2004-09-01), Munson et al.
patent: 2005/0203072 (2005-09-01), Rudolph et al.
patent: 1291345 (2003-03-01), None
patent: 2001247569 (2001-09-01), None
patent: WO 9111172 (1991-08-01), None
patent: WO 9402518 (1994-02-01), None
patent: WO 9625157 (1996-08-01), None
patent: WO 9740028 (1997-10-01), None
patent: WO 9852937 (1998-11-01), None
patent: WO 9852940 (1998-11-01), None
patent: WO 9852941 (1998-11-01), None
patent: WO 9855148 (1998-12-01), None
patent: WO 9932106 (1999-07-01), None
patent: WO 9958523 (1999-11-01), None
patent: WO 0005999 (2000-02-01), None
patent: WO 0031063 (2000-06-01), None
patent: WO 0031065 (2000-06-01), None
patent: WO 0035298 (2000-06-01), None
patent: WO 0040243 (2000-07-01), None
patent: WO 0043384 (2000-07-01), None
patent: WO 0157038 (2001-08-01), None
patent: WO 02072579 (2002-09-01), None
patent: WO 03005999 (2003-01-01), None
patent: WO 03044021 (2003-05-01), None
patent: WO 03059891 (2003-07-01), None
patent: WO 03068223 (2003-08-01), None
patent: WO 03068230 (2003-08-01), None
patent: WO 03087087 (2003-10-01), None
patent: WO 03104223 (2003-12-01), None
patent: WO 2004004720 (2004-01-01), None
patent: WO 2004072072 (2004-08-01), None
patent: WO 2004078116 (2004-09-01), None
patent: WO 2004087677 (2004-10-01), None
patent: WO 2004100946 (2004-11-01), None
patent: WO 2004048948 (2005-06-01), None
Ma N et al., Zhonghua nei ke za zhi [Chinese journal of internal medicine], (Aug. 1999) vol. 38, No. 8, pp. 523-526.
Hodge et al., Clinical and experimental immunology, 2007, vol. 150, No. 1, pp. 22-29.
Toghe et al., Eur. J. Immunol. (2007), vol. 37, pp. 768-779.
Russo et al., Clinical Science (2005), vol. 109, pp. 135-142.
Yasuda et al., Respiratory Medicine (1998), vol. 92, pp. 993-999.
Zhang Jinnoug et al., Journal of Huazhong University of Science and technology (2007), vol. 27(5), pp. 505-507.
Escott et al., British journal of Pharmacology (2000), vol. 131, pp. 173-176.
Ma N et al., Zhonghua nei ke za zhi [Chinese journal of internal medicine], (Aug. 1999) vol. 38, No. 8, pp. 523-526 (translation).
Mellor, et al., “Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R”, Proceedings of the National Academy of Sciences of the United States of America, 2003, pp. 11589-11593, vol. 100(20).
Regan, et al., “Pyrazole Urea-Based Inhibitors of p38 Map Kinase: From Lead Compounds to Clinical Candidate”, Journal of Medicinal Chemistry, 2002, pp. 2994-3008, vol. 45, No. 14.
Haleblian, John K., “Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications”, Journal of Pharmaceutical Sciences, Aug. 1975, pp. 1269-1288, vol. 64, No. 8.
Liang, Alfred, et al., “Fast-dissolving intraoral drug delivery systems”, Expert Opinion it Therapeutic Patents, WO2001, pp. 981-986, vol. 11, No. 6.
*English equivalent to AP200557105 A (2005).
Underwood et al., Journal of Physiology (2000), 279 (5, Pt. 1), L895-L908.
Underwood et al., Journal of Pharmacology and Experimental Therapeutics (2000), 293(1), 281-288.
Adcock et al., Biodrugs (2004), 18(3), 167-180.
Underwood et al., Progress in Respiratory Research (2001), 31 (New Drugs for Asthma, Allergy and COPD), 342-345.
*WO 99/32106 is equivalent to EP1047418.
Dominguez et al., Expert Opinion Ther. Patents, 15(7), pp. 801-816, 2005.
Jerome et al., Bioorganic & Medicinal Chem. Letters, 20, pp. 469-473, 2010.
Regan et al., J. Med. Chem., 46, pp. 4676-4686, 2003.
White et al., J. Med. Chem., 39, pp. 4382-4395, 1996.
Vicentini et al., Heterocycles, 32(4), pp. 727-734, 1991.
Kroe et al., J. Med. Chem., 46, pp. 4669-4675, 2003.
McCurdy et al., Journal of Medicinal Chemistry, 45(14), pp. 2887-2890.
Regan, Bioorganic & Medicinal Chemistry Letters, 13, pp. 3101-3104, 2003.
Saklatvala, Current Opinion in Pharmacology, 4, pp. 372-377, 2004.
Schieven, Current Topics in Medicinal Chemistry, 5, pp. 921-928, 2005.
Wadsworth, The Journal Of Pharmacology and Experimental Therapeutics, 291(2), pp. 680-687, 1999.
Zhou et al., Clinical Immunology, 90(3), pp. 232-238, 1999.
Zu et al., Journal of Immunology, 160, pp. 1982-1989, 1998.
Chem. Abstract, 116(21), May 1992, abstract No. 214456r.
Newton et al., BioDrugs, 17(2), pp. 113-129, 2003.
Barnes et al., Current Opinion Pharmacology, 4(3), p. 263-272, 2004.
Beisswen er et al., Respiration, 71(4), p. 402-409, 2004.
Hashimoto et al., The Journal of Pharmacology and Experimental Therapeutics, 293(2), p. 370-375, 2000.
Underwood et al., Am. J. Physiol. Lung Cell Mol. Physiol., 279(5), p. L895-L902, 2000.
Vuillemenot et al., Am. J. Respir. Cell Mol. Biol., 30(4), pp. 438-448, 2004.
Shum et al., American Journal Of Respiratory and Critical Care Medicine, 162(5), p. 1925-1931, 2000.
Choi et al., Tuberculosis and Respiratory Diseases, 45(6), p. 1236-1251, 1998.
Blease et al., Expert Opinion Emerging Drugs, 8(1), pp. 71-81, 2003.
Johnson et al., Science, 298(5600), p. 1911-1912, 2002.
Underwood et al., J. Pharmacol. Exp. Ther. 293(1), p. 281-288, 2000.
Irusen et al., J. Allergy Clin. Immunol. 109(4), p. 649-657, 2002.
Donnelly et al., Drugs, 63(19), p. 1973-1998, 2003.
Bayer AG, Expert Opinion On Therapeutic Patents, 13(10), p. 1663-1666, 2003.
Barnes, Respiration, 68(5), p. 441-448, 2001.
Sethi et al., Chest, 118(6), p. 1557-1565, 2000.
Zhang et al., Am. J. Respir. Cell Mol. Biol., 24(2), p. 123-131, 2001.
Yoshinari et al., Crit. Care Med., 29(3), p. 628-634, 2001.
Dunican et al., Shock, 14(3), p. 284-289, 2000.
Matsuoka et al., Am. J. Physiol. Lung Cell Mol. Physiol, 283(1), p. L103-L112, 2002.
Churg et al., Am. J. Respir. Crit. Care Med., 166(6), p. 849-854, 2002.
Fujita et al., Am. J. Physiol. Lung Cell Mol. Physiol., 280(1), p. L39-L49, 2001.
Churg et al., Am. J. Respir Crit. Care Med., 170(5), p. 492-498, 2004.
Barnes et al., Ann. 1st Super Sanita, 39(4), p. 573-582, 2003.
Barnes et al., Novartis Found Symp, 234, p. 255-272, 2001.
Denham et al., Crit. Care Med., 28(7), p. 2567-2572, 2000.
Jeffery, European Respiratory Review, 7(4 ), p. 111-118, 1997.
Lewthwaite Russell Andrew
Mathias John Paul
Millan David Simon
Phillips Christopher
Joran A. David
Pfizer Inc.
Rahmani Niloofar
Ronau Robert T.
Seaman D M
LandOfFree
Triazolopyridinylsulfanyl derivatives as P38 map kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolopyridinylsulfanyl derivatives as P38 map kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyridinylsulfanyl derivatives as P38 map kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4253819